NCT05905289Completed
Survival and Reproductive Outcomes of Malignant Ovarian Germ Cell Tumors
Survival and Reproductive Outcomes After Fertility-sparing Surgery and Adjuvant Chemotherapy in Malignant Ovarian Germ Cell Tumors
Source: ClinicalTrials.gov · Last updated 9 Feb 2024
Brief summary (registry, in English)
Malignant ovarian germ cell tumor patients conducted fertility-sparing surgery and adjuvant chemotherapy in Kasr El-Aini Hospital - Faculty of Medicine - Cairo University from January 2012 to December 2016 will be retrospectively investigated.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 27 (actual)
- First submitted
- 7 Jun 2023
- Start date
- 1 May 2023
- Primary completion date
- 11 Dec 2023
- Lead sponsor
- Cairo University
- Diseases
- Ovarian cancer
- NCT number
- NCT05905289
What you commit to
- Study type: Observational
- Participants enrolled: 27
- From 1 May 2023 to the primary completion date, 11 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent malignancy.
Other
- Patients with benign ovarian germ cell tumors e.g. mature teratoma.
- Severe comorbidities that may affect ovarian reproductive function.
Who the study is looking for
- Age : younger than 35 years old at first treatment.
- Fertility-sparing surgery and adjuvant chemotherapy.
- Pathological diagnosis of malignant ovarian germ cell tumor.
Age in the registry: 18 years to 35 years · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Obstetrics & Gynecology Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.